Polina Rusina

Polina Rusina

Auto-generated profile, based on publicly available information

Polina Rusina

Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Russian Chemical Reviews
Verified
Journal Article
Closed access
ITIlya Yu. Titov
Ilya Yu. Titov
VSVictor Stroylov
Victor Stroylov
PRPolinaV. Rusina
PolinaV. Rusina
ISIgor V. Svitanko
Igor V. Svitanko
The review aims to present a classification and applicability analysis of methods for preliminary molecular modelling for targeted organic, catalytic and biocatalytic synthesis. The following three main approaches are considered as a primary classification of the methods: modelling of the target – ligand coordination without structural information on both the target and the resulting complex; calculations based on experimentally obtained structural information about the target; and dynamic simulation of the target – ligand complex and the reaction mechanism with calculation of the free energy of the reaction. The review is meant for synthetic chemists to be used as a guide for building an algorithm for preliminary modelling and synthesis of structures with specified properties. The bibliography includes 353 references.

1 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YTYakov Tsepilov
Yakov Tsepilov
DSDaniel Suveges
Daniel Suveges
DCDaniel Considine
Daniel Considine
SSSzymon Szyszkowski
Szymon Szyszkowski
XGXiangyu Jack Ge
Xiangyu Jack Ge
DODavid Ochoa
David Ochoa
Genetic support for drug targets substantially increases clinical success rates, establishing genome-wide association studies (GWAS) as central to therapeutic hypothesis generation. However, the same genetic evidence that reveals causal gene–disease relationships simultaneously exposes organism-level safety liabilities—a dimension requiring principled, genome-wide quantification. Here we systematically analyse 100,526 GWAS to yield 789,453 credible sets and gene prioritisations for 15,641 genes, with discovery showing no saturation as GWAS expand and increase diversity. We find that 64% of GWAS-implicated genes are pleiotropic, associated with traits across multiple diseases and showing a non-linear relationship between the degree of pleiotropy and clinical success. Highly pleiotropic genes—concentrated in immune, inflammatory, and oncogenic signalling programmes—are enriched in safety-terminated clinical programmes, mouse lethal knockouts, and cancer driver genes, establishing gene-level pleiotropy as a potential measure of genetically-informed organism-level safety liability. Protein-altering variant (PAV) support amplifies therapeutic signal (OR = 6.0), yet PAV targets show higher average pleiotropy, introducing a competing safety liability. Combining PAV support with intermediate pleiotropy (2–5 therapeutic areas) resolves this tension, yielding OR = 10.3 and relative success = 4.8—a profile already satisfied by 52 approved therapies. As GWAS continue to expand in scale and resolution, these findings lay the groundwork for increasingly sophisticated target discovery strategies that yield safer and more effective therapeutic hypotheses.

26 November 2025 in BioHackrXiv
Verified
Preprint
Open access
MPMina P. Peyton
Mina P. Peyton
CCCheng-Han Chung
Cheng-Han Chung
SMSamarpan Mohanty
Samarpan Mohanty
VTVan Q. Truong
Van Q. Truong
ASAndrew Scouten
Andrew Scouten
BBBen Busby
Ben Busby
Knowledge graphs (KGs) and large language models (LLMs) are increasingly applied in biomedical research; however, LLMs' tendency to hallucinate and lack of evidence traceability poses significant challenges for rigorous scientific applications. To address these limitations, the NVIDIA - AWS Open Data Knowledge Graph Hackathon, which brought together transatlantic teams, catalyzed the development of novel frameworks that built or integrated KGs with graph-based retrieval-augmented generation (GraphRAG) to enhance evidence-grounded generative AI. The hackathon took place on October 1-3, 2025, at two locations - the AWS Skills Center in Arlington, VA, USA and the European Bioinformatics Institute (EBI) Training Center in Cambridge, UK. Across seven prototype projects, participating teams developed systems that construct, validate, and deploy biomedical KGs using open data and cloud-native infrastructure. These included GeNETwork, which integrates pediatric oncology datasets to identify therapeutic targets; ECoGraph, a multi-omics graph framework for characterizing colorectal cancer drivers; ClassiGraph, a graph neural network classifier for cancer subtypes; EasyGiraffe, a validator for multisite polygenicity extraction; MIDAS (Model Integration and Data Assembly System), a pipeline for harmonizing heterogeneous biomedical datasets; KG Model Garbage Collection, a framework for detecting and pruning erroneous AI-generated edges; and BioGraphRAG, which combines precision medicine and literature-derived KGs for evidence-based question answering. Together, these prototypes demonstrate practical strategies for constructing and deploying biomedical KGs and highlight the potential of GraphRAG to produce interpretable, verifiable AI-driven insights. By emphasizing open data, reproducible pipelines, and evidence-grounded reasoning, this work advances methodologies for trustworthy generative AI in biomedical discovery.

16 September 2026 in Drug Discovery Today
Verified
Journal Article
Open access
PRPolina Rusina
Polina Rusina
DODavid Ochoa
David Ochoa
FRFranck Rapaport
Franck Rapaport
SKShameer Khader
Shameer Khader
EMEllen M. McDonagh
Ellen M. McDonagh